349 related articles for article (PubMed ID: 31277279)
1. Possible Biomarkers for Cancer Immunotherapy.
Otoshi T; Nagano T; Tachihara M; Nishimura Y
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31277279
[TBL] [Abstract][Full Text] [Related]
2. Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer.
Raimondi A; Sepe P; Zattarin E; Mennitto A; Stellato M; Claps M; Guadalupi V; Verzoni E; de Braud F; Procopio G
Front Oncol; 2020; 10():1644. PubMed ID: 32903369
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
4. From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy.
Sesma A; Pardo J; Cruellas M; Gálvez EM; Gascón M; Isla D; Martínez-Lostao L; Ocáriz M; Paño JR; Quílez E; Ramírez A; Torres-Ramón I; Yubero A; Zapata M; Lastra R
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33066479
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for response to immunotherapy in hepatobiliary malignancies.
Lin ZF; Qin LX; Chen JH
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):413-419. PubMed ID: 35973935
[TBL] [Abstract][Full Text] [Related]
6. Cancer neoantigens as potential targets for immunotherapy.
Ma W; Pham B; Li T
Clin Exp Metastasis; 2022 Feb; 39(1):51-60. PubMed ID: 33950415
[TBL] [Abstract][Full Text] [Related]
7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
8. Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges.
Yang F; Wang JF; Wang Y; Liu B; Molina JR
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008273
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies.
Maung TZ; Ergin HE; Javed M; Inga EE; Khan S
Cureus; 2020 May; 12(5):e8095. PubMed ID: 32542150
[TBL] [Abstract][Full Text] [Related]
10. Gut microbiome modulates efficacy of immune checkpoint inhibitors.
Yi M; Yu S; Qin S; Liu Q; Xu H; Zhao W; Chu Q; Wu K
J Hematol Oncol; 2018 Mar; 11(1):47. PubMed ID: 29580257
[TBL] [Abstract][Full Text] [Related]
11. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
[TBL] [Abstract][Full Text] [Related]
12. Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs).
Giustini N; Bazhenova L
Lung Cancer (Auckl); 2021; 12():21-34. PubMed ID: 33790679
[TBL] [Abstract][Full Text] [Related]
13. Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy.
Honrubia-Peris B; Garde-Noguera J; García-Sánchez J; Piera-Molons N; Llombart-Cussac A; Fernández-Murga ML
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503087
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
15. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
16. Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer.
Kang BW; Chau I
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817133
[TBL] [Abstract][Full Text] [Related]
17. Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?
Costantini A; Takam Kamga P; Dumenil C; Chinet T; Emile JF; Giroux Leprieur E
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31470546
[TBL] [Abstract][Full Text] [Related]
18. Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors.
Chen JA; Ma W; Yuan J; Li T
Cancer Treat Res; 2020; 180():251-279. PubMed ID: 32215873
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers for predicting the efficacy of immune checkpoint inhibitors.
Wang C; Wang HN; Wang L
J Cancer; 2022; 13(2):481-495. PubMed ID: 35069896
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers in immunotherapy: literature review and future directions.
Pharaon R; Koczywas MA; Salgia S; Mohanty A; Massarelli E
J Thorac Dis; 2020 Sep; 12(9):5119-5127. PubMed ID: 33145089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
